Leading Life Science R&D Organizations Talk About Synthace

"Synthace allows us to think outside the box, and do things we couldn't do before"

André Raposo, Group Lead - Computer-Aided Biology (CAB) group at Oxford Biomedica, talks about Synthace supporting business growth

"We've used Synthace in combination with our own techniques and modelling to close the loop on synthetic genetic network engineering"

Paul Grant, Synthetic Biologist at Microsoft Research, talks about the importance of lab automation and how Microsoft is utilizing Synthace to facilitate automation in their labs

"Synthace enables us to approach more complex problems by removing the limitations of human error or long completion times"

Matthew Jones, Principal Synthetic Biologist at Cambridge Consultants, talks about how they can do more in their labs with the support of automation

"A better, more traceable automation platform that partners can benefit from when they work with us"

Juan Jose Guijarro Leach, Senior Analytical Development Scientist at the Cell and Gene Therapy Catapult, talks about how he uses Synthace to demonstrate to potential clients the value of working with his lab

"A very intuitive platform for describing and executing complex experiments"

Marc-Olivier Baradez, Head of Data Sciences at the Cell and Gene Therapy Catapult, describes Synthace as an intuitive platform that gets his business the results they need

"The benefits of the efficiency improvements provide lower cost solutions to end users"

David Pollard, Head of New Materials & Components, Corporate Research, Sartorius Stedim, talks about how end users and patients benefit from engineered biology